From the CEO

Peptonic's strategy shift in 2022 has set the company in a positive direction

Despite current society-wide challenges, Peptonic's growth in 2022 showed a clearly positive trend. Q4 2022 was the third financial quarter in a row that had significant improvement compared to the one before it. The primary reason for the trend is a successful strategy shift that was made at the beginning of 2022 in connection with the incorporation of Israeli CommonSense, which was acquired at the end of 2021 and is now Peptonic Israel.

At the beginning of 2022, the company divided its business into two areas: Medical Consumer — featuring Intimate self-care products that are clinically proven and based on a concept of “diagnose, treat, prevent” — and LifeStyle Consumer — featuring solutions composed mainly of durable menstrual products. The separation created greater clarity, both internally and externally, which has improved focus, cost efficiency, and consumer reception. That, in turn, has improved company performance.  The Medical Consumer business area currently accounts for approximately two-thirds of Peptonic's turnover.

Strong reception to the “diagnose, treat, prevent” concept

Peptonic created a unifying concept within its Medical Consumer portfolio of products. The solutions are connected by the ability they offer consumers to diagnose, treat, and prevent vaginal health issues themselves. So far, the concept has been received with great interest. Peptonic's vaginal self-tests were presented at the annual conference of Sweden’s national association of gynecologists, SFOG 2022, and given a very positive reception. In the spring of 2023, Peptonic will launch an educational project for Swedish gynecologists regarding the products' usage and benefits. The response from pharmacies in Sweden has also been very positive, and all of the major chains now list Peptonic's self-test for vaginal infections for digital purchase. The company expects the expansion of pharmacy distribution to continue  in 2023. In 2022, Peptonic's Medical Consumer products grew organically by more than 50% in its home market of Sweden.

Increasing interest from international partners

International demand for Peptonic’s products increased throughout 2022. This was, above all, mostly regarding the company's vaginal self-tests. Existing partners such as Bayer, Exeltis, Walgreens, and CVS regularly ordered significant product volumes. New distributor agreements were signed with Windsor Pharma for Central America, German Medical Store for the United Arab Emirates, and InVivo Pharma for Georgia. The company expects more distributor agreements in 2023 and plans to add Peptonic’s gel treatment for vaginal dryness and preventive intimate cleanser to select distribution agreements for international markets where the vaginal self-tests are already sold.

Lunette’s contract agreement with the UN — an important signal of quality

In 2022, Peptonic's LifeStyle Consumer business area also saw significant success for its Lunette brand. With Lunette, the company works hard to break stigmas and be an inclusive source of information and education about women’s health. As a result of those efforts, Lunette was awarded a long-term contract by the UN in 2022. Lunette was chosen as the supplier of menstrual cups for the UN’s hygiene kits. The first orders for the contract were placed at the end of 2022. This contract agreement not only has significant potential for future business but is a very public signal indicating the high quality of Peptonic's Lunette brand.

Growing patent portfolio

An important part of Peptonic's strategy is to develop innovations and protect them with patents. In 2022, Peptonic's vaginal gel gained international approval for the treatment of vestibulitis. An adapted version of the gel also gained international approval for the treatment of vaginal fungal infections, which applies to the company's moisturizing intimate cleanser as well.

Successful fundraising to create conditions for profitability

Peptonic has just closed the first part of an ongoing round of funding. It’s financing that, with a rights issue and the associated warrant series, should give the company the conditions to implement strategy and become profitable. In response to the rights issue, which ended in February 2023, the company raised SEK 55 million before issue costs of which amounted to approximately SEK 10 million, of which SEK 4.9 million referred to guarantee compensation. Given the current financial climate, this was a very successful result. The proceeds will be used to accelerate the development of the product portfolio, strengthen the organization, increase marketing, and repay loans. In connection with the rights issue, Maida Vale Capital became a new major shareholder alongside the Vidarstiftelsen foundation. Maida Vale's commitment to Peptonic is long-term and brings added value to the company with extensive industry experience and global networks.

I, along with the entire organization, feel confident about the company's future.

Erik Sundquist

CEO

KEY FIGURES
Peptonic Group
		12 mon	12 mon	12 mon
		jan-dec	jan-dec	jan-dec
		2022	2021	2020
Sales goods, KSEK		43 634	31 643	21 283
Gross profit sales goods, KSEK		23 394	19 070	13 089
Gross margin, %		54%	60%	61%
Operating profit, KSEK		-33 606	-73 718	-31 053
Return on equity,%		Neg	Neg	Neg
Equity ratio,%		55	62	88
Earnings per share, SEK		-0.15	-0.38	-0.19
Liquidity per share, SEK		0.01	0.05	0.24
Equity per share, SEK		0.19	0.27	0.72
Share price per closing, SEK		0.14	0.63	1.73
Share price/Equity per share, SEK		0.72	2.30	2.39
Equity per share, SEK		242 743 544	191 639 642	162 911 613

FINANCIAL INFORMATION

Group

Revenue – Sales of goods during the fourth quarter amounted to SEK 10,191 (5,642) thousand, a growth of 80,6%. Other operating income for the quarter was SEK 1,733 (610) thousand and mainly consists of exchange rate adjustments and covid support.

In the full year, sales of goods amounted to SEK 43,634 (31,643) thousand corresponding to a sales increase of 37.9%. Other operating income for the period was SEK 2,770 (622) thousand.

Costs – Costs for the fourth quarter amounted to SEK -18,814 (-50,226) thousand. Costs for the full year were SEK -80,010 (-105,983) thousand.

Costs of goods sold for the quarter amounted to SEK -5,890 (-2,254) thousand, which corresponds to a gross profit of SEK 4,302 (3,388) thousand and a gross margin of 42% (60%). The relatively low gross profit and margin for the quarter is mainly explained by inventory adjustments which fully charged quarter 4 instead of being distributed over previous quarters. If the cost had been distributed over previous quarters, the fourth quarter's gross profit and gross margin would have amounted to SEK 5,313 thousand and 52%, respectively, which is in line with the company's gross profit and margin for the full year. This is slightly lower than the previous year which is related to, through the acquisition of Commonsense Israel, inherited license business.

 
Profit – The group's result after net financial items for the fourth quarter amounted to SEK -8,122 (-43,858) thousand. For the full year, the corresponding result is SEK -36,857 (-73,688) thousand.

Financial position and liquidity – Cash and bank as of December 31, 2022, amounted to SEK 3,566 (10,153) thousand.

With the rights issue of units carried out in January 2023, approx. SEK 55 million will be added to the company before issue costs. Net balance after payment of long-term liabilities and after issue costs amounts to approx. SEK 22 million, which strengthens the group's financial position and enables the company to continue developing the product portfolio and switch up production and sales within all of the group's business areas.

Shareholders equity – The group's equity as of 31 December 2022 amounted to SEK 47,091 (52,017) thousand, which gives an equity ratio of 55 (62) percent.

Liabilities – The group's liabilities amounted, as of 31 December 2022, to SEK 38,660 (31,483) thousand. Of which short-term amounts to SEK 35,066 thousand. Of these, SEK 19,331 thousand have been repaid in connection with the rights issue.

Organization – During the period, the average number of employees was 34 (34). At the end of the period, the number of employees amounted to 34 (34).

INCOME STATEMENT
Peptonic Group
		3 mon	3 mon	12 mon	12 mon
		oct-dec	oct-dec	jan-dec	jan-dec
KSEK	Note	2022	2021	2022	2021
Operating income
Sales of products		10 191	5 642	43 634	31 643
Other operating income		1 733	610	2 770	622
Total operating income		11 924	6 252	46 404	32 265
Operating expenses
Cost of goods		-5 890	-2 254	-20 239	-12 573
Other external expenses	1	-7 405	-14 876	-34 186	-45 690
Personnel costs		-4 585	-8 905	-21 922	-19 430
Depreciation		-885	-24 409	-3 491	-27 055
Other operating costs		-49	218	-172	-1 234
Total operating expensses		-18 814	-50 226	-80 010	-105 983
Operating loss		-6 890	-43 974	-33 606	-73 718
Net financial income/expense		-1 232	116	-3 251	30
Loss before taxes		-8 122	-43 858	-36 857	-73 688
Taxes		0	0	0	0
Net loss for the period		-8 122	-43 858	-36 857	-73 688

BALANCE SHEET
Peptonic Group
		31-dec	31-dec
KSEK	Note	2022	2021
Assets
Non-Current assets
Intangeble assets	2	50 098	52 210
Tangeble assets	3	4 299	4 204
Financial assets		0	0
Total non-current assets		54 398	56 414
Current assets
Stock		15 368	10 323
On going fund raising		0	0
Other receivbles		8 267	5 166
Tax receivable		89	524
Prepaid expenses and accrued income		4 064	920
Liquid assets		3 566	10 153
Total current assets		31 354	27 086
Total assets		85 752	83 500

CHANGES IN EQUITY
Peptonic Group
KSEK		Share Capital	Develop-ment cost fund	Ongoing right issue	Share Premium reserve non-restricted	Accumul-ated losses	Total shareholders equity
Opening balance January 1, 2020		16 291	11 186	2 327	240 399	-152 383	117 820
Net loss for the year						-73 688	-73 688
Transfering fund			-1 569			1 569	0
Right issue		2 873		-2 327	6 954		7 500
On going right issues						400	400
Issue expenses					-15		-15
Closing balance December 31, 2020		19 164	9 617	0	247 338	-224 102	52 017
Opening balance January 1, 2021		19 164	9 617	0	247 338	-224 102	52 017
Net loss for the year						-36 857	-36 857
Transfering fund			-2 225			2 225	0
Right issue		5 110			26 667		33 728
On going right issues				0			0
Coneversion difference						547	547
Issue expenses							-3 444
Closing balance December 31, 2021		24 274	7 392	0	274 005	-258 187	45 992

STATMENT OF CASH FLOW
Peptonic Group
		12 mon	12 mon
		jan-dec	jan-dec
KSEK		2022	2021
CASH FLOW FROM OPERATIONS BEFORE CHANGES IN WORKING CAPITAL
Operating profit/loss		-36 857	-73 688
Non-cash flow items		3 491	26 840
Paid tax		0	0
NET CASH FLOW FROM OPERATING ACTIVITIES BEFORE CHANGES IN WORKING CAPITAL		-33 366	-46 848
Increase (-) decrease (+) inventory		-5 045	-4 190
Increase (-) decrease (+) receivables		-5 810	3 333
Increase (-) decrease (+) liabilities		-357	7 365
NET CASH FLOW FROM OPERATING ACTIVITIES		-44 579	-40 340
CASH FLOW FROM INVESTING ACTIVITIES
Investment in immaterial assets, net		-987	-1 256
Investment in material assest, incl subsidaries		0	-3 024
Investment in financial assets, net		0	0
Divestment / reduction of  financial assets		1 184	0
NET CASH FLOW FROM INVESTING ACTIVITIES		197	-4 280
CASH FLOW FROM FINANCING ACTIVITIES
Rights issue		33 704	7 500
Issue expenses		-3 444	-15
Bridgeloan		7 534	7 500
NET CASH FLOW FROM FINANCING ACTIVITIES		37 794	14 985
TOTAL CASH FLOW FOR THE YEAR		-6 587	-29 159
Cash and cash equivalents at beginning of period		10 153	39 312
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD		3 566	10 153

Audit

This year-end report has not been subject to be reviewed by the company's auditors.

Proposal for allocation of profit

The board proposes that no dividends are paid for the financial year 2022.

Assurance

The board and the managing director assure that the year-end report provides a fair overview of the company's operations, position and results.

FINANSIELL KALENDER

Year-end report, 2022                                                                                             2023-02-24

Annual General Meeting                                                                                         2023-04-20

Quarterly report, 1                                                                                                   2023-04-24

Quarterly report, 2                                                                                                   2023-08-11

Quarterly report, 3                                                                                                   2023-10-24

Year-end report, 2023                                                                                       2024-02-23

The annual general meeting will be held on April 20, 2023, in Stockholm. The annual report will be available on the Company's website, www.peptonicmedical.se, no later than 3 weeks before the general meeting and can then also be requested from the Company by e-mail erik.sundquist@peptonicmedical.se.

Stockholm on 24th February, 2023

Jan Bardell, Chairmen of the Board                                        Daniel Rudeklint, Board member

Anders Blom, Board member                                                 Anders Norling, Board member

Erik Sundquist, CEO

For more information please contact:

Erik Sundquist, CEO PEPTONIC Medical AB. Phone: +46 722 499 043

 

ABOUT Peptonic Medical AB

Peptonic is a Swedish innovative biomedical company that conducts research, development and sales of medical treatments and lifestyle products in the field of women's health. Peptonic has divided its operations into two business areas: "Medical Consumer" and "Lifestyle Consumer". The business area "Medical Consumer" is based on clinically proven intimate self-care and constitutes the company's main focus and is sold under the VagiVital brand. The "Lifestyle Consumer" business area consists of lifestyle products with a focus on sustainable menstrual products and is sold under the Lunette brand. The company was founded in 2009 and the stock has been traded since 2014 on Spotlight (www.spotlightstockmarket.com) in Stockholm